Challenges of characterizing proarrhythmic risk due to QTc prolongaton induced by nonadjuvant anticancer agents

Expert Opinion on Drug Safety

Volumn 7, Issue 3, 2008, Pages 305-318

  Sarapa, Nenad ^a   Britto, Margaret R ^b  

^a Johnson and Johnson PRD   (United States)

^b IQVIA   (United States)

Author keywords

ICH E14; Oncology; QTc prolongation; Thorough QTc study

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ABARELIX; AMSACRINE; ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BORTEZOMIB; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTOTOXIC AGENT; DASATINIB; FLUOROURACIL; GRANISETRON; IXABEPILONE; KETOCONAZOLE; LAPATINIB; METHADONE; MOXIFLOXACIN; NEUROLEPTIC AGENT; PLACEBO; PYRROLE DERIVATIVE; SUNITINIB; VORINOSTAT;

CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE PREDISPOSITION; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; ECG ABNORMALITY; ELECTROCARDIOGRAM; HEART CONDUCTION; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART RHYTHM; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; LOADING DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NONHUMAN; POSTMARKETING SURVEILLANCE; QT INTERVAL; QT PROLONGATION; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SIDE EFFECT; SINGLE DRUG DOSE; SUDDEN DEATH; TORSADE DES POINTES; CHEMICALLY INDUCED DISORDER; DRUG APPROVAL; DRUG LABELING; ELECTROCARDIOGRAPHY; INTERNATIONAL COOPERATION; LONG QT SYNDROME; PATHOPHYSIOLOGY; PRACTICE GUIDELINE;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; DRUG LABELING; ELECTROCARDIOGRAPHY; HUMANS; INTERNATIONAL COOPERATION; LONG QT SYNDROME; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; TORSADES DE POINTES;

EID: 44949175102     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.3.305     Document Type: Review

References (97)

1. Viskin S. Long QT syndromes and torsades de pointes. Lancet 1999;354:1625-33
2. Shah RR. Drug-induced prolongation of the QT interval - why the regulatory concern? Fundam Clin Pharmacol 2002;16:119-24
3. Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004;15:475-95
4. Stockbridge N, Throckmorton DC. Regulatory advice on evaluation of the proarrhythmic potential of drugs. J Electrocardiol 2004;37(Suppl):40-1
5. Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol 2006;46:498-507
6. Kowey PR, Malik M. The QT interval as it relates to the safety of non-cardiac drugs. Eur Heart J 2007;9(Suppl G):G3-8
7. ICH E14 Guidance for Industry. Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. International Conference on Harmonization, October 2005. Available from: http://www.fda.gov/cber/gdlns/iche14qtc.pdf
8. de Jonge M, Verweij J. QTc prolongation and/or oncology drug development: Who's in danger? Eur J Cancer 2008;44(4):486-7
9. Fingert H, Varterasian M. Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular safety and risk management. AAPS J 2006;8:E89-94
10. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007;25:3362-71
11. Charbit B, Funck-Brentano C, Samain E, et al. QT interval prolongation after oxytocin bolus during surgical induced abortion. Clin Pharmacol Ther 2004;76:359-64
12. Common Terminology Criteria for Adverse Events. Version 3.0. National Cancer Institute Cancer Therapy Evaluation Program, 2006 August 9. Available from: http://ctep.cancer.gov/forms/CTCAEv3.pdf
13. Jones RL, Swanton CS, Ewer MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2006;5:791-809
14. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther 2006;6:1249-69
15. de Castro G, Awada A. Side effects of anticancer molecular-targeted therapies (not monoclonal antibodies). Curr Opin Oncol 2006;18:307-15
16. Yeh ETH. Cardiotoxicity induced by chemotherapy and antibody therapy. Ann Rev Med 2006;57:485-98
17. Youssef G, Links M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am J Cardiovasc Drugs 2005;5:233-43
18. Schwartz CL, Hobbie WL, Truesdell S, et al. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 1993;11:1906-10
19. Iwata N, Karasawa M, Omine M, et al. Aclarubicin-associated QTc prolongation and ventricular fibrillation. Cancer Treat Rep 1984;68:527-9
20. Curigliano G, Cipolla C, Sessa C, et al. What is the role of QTc prolongation assessment in new drugs development phase I oncology trials? J Clin Oncol 2006;20(Suppl): abstract 2006
21. Mann DL. Targeted cancer therapeutics: the heartbreak of success. Nat Med 2006;12:881-2
22. Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006;12:3997-4003
23. Fouladi M, Furman WL, Chin T, et al.; Children's Oncology Group. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: A children's oncology group report. J Clin Oncol 2006;24:3678-85
24. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-28
25. Marshall JL, Rizvi N, Kauh J, et al. A Phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2002;2:325-32
26. Rowinsky EK, de Bono J, Deangelo DJ, et al. Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies. J Clin Oncol 2005;23(16S):3131
27. Cooney MM, Radivoyevitch T, Dowlati A, et al. Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004;10:96-100
28. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16:1391-7
29. Tamura T, Minami H, Yamada Y, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006;1:1002-9
30. Kovacs MJ, Reece DE, Marcellus D, et al. A phase II study of ZD6474 (Zactima), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma - NCIC CTG IND.145. Invest New Drugs 2006;24:529-35
31. Carducci MA, Musib L, Kies MS, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006;24:4092-9
32. Zolinza™ (vorinostat) Package Insert. Merck & Co. Inc., Whitehouse Station. NJ, USA [update 2006 November]. Available from: http://www.merck.com/product/usa/pir_circulars/z/zolinza/ zolinza_pi.pdf
33. Tykerb™ (lapatinib) Package Insert. GlaxoSmithKline, Research Triangle Park, NC, USA [update 2007 March]. Available from: http://us.gsk.com/products/assets/us_tykerb.pdf
34. Sprycel™ (dasatinib) Package Insert. Bristol Myers Squibb, Princeton, NJ, USA. 2006 July. Available from: http://www.bms.com/ cgi-bin/anybin.pl?sql=select%20PPI%20from%20TB_PRODUCT_PPI% 20where%20PPI_SEQ=113&key=PPI
35. Sutent™ (sunitinib) Package Insert. Pfizer Labs, New York, NY, USA [update 2007 February]. Available from: http://www.pfizer.com/pfizer/ download/uspi_content.pdf
36. Stupp R, Bauer J, Pagani O, et al. Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. Ann Oncol 1998;9:1233-42
37. Vertex Pharmaceuticals Press Release. 20 November 2007. Available from: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=276543
38. Williams G, Pazdur R. Regulatory considerations in clinical trials of novel anticancer drugs. In: Adjei AA, Buolamwini JK, editors, Novel anticancer agents: strategies for discovery and clinical testing. Elsevier, Inc.; Baltimore, USA 2006. p. 263-84
39. Bednar MM, Harrigan EP, Anziano RJ, et al. The QT interval. Prog Cardiovasc Dis 2001;43:1-45
40. Goodin S, Cunningham R. 5-HT3-Receptor antagonists for the treatment of nausea and vomiting: A reappraisal of their side-effect profile. Oncologist 2002;7:424-36
41. Ellis P, Dozier N. Evidence for equivalent electrocardiographic changes among the 5-HT3 receptor antagonists. Oncologist 2003;8:216-8
42. Walker G, Wilcock A, Carey AM, et al. Prolongation of the QT interval in palliative care patients. J Pain Symptom Manage 2003;26:855-9
43. Reddy S. Oral methadone for cancer pain: No indication of QT interval prolongation or Torsades de Pointes. J Pain Symptom Manage 2004;28:301-3
44. Tei Y, Morita T, Inoue S, Miyata H. Torsades des Pointes caused by a small dose of risperidone in a terminally ill cancer patient. Psychosomatics 2004;45:450-1
45. Philips JA, Marty FM, Stone RM, et al. Torsades de pointes associated with voriconazole use. Transpl Infect Dis 2007;9:33-6
46. University of Arizona Health Sciences Center, Center for Education and Research on Therapeutics. Drugs that prolong the QT interval and/or induce Torsades de Pointes ventricular arrhythmia. 2008. Available from: http://www.torsades.org/medical-pros/drug-lists/drug-lists.htm
47. Varterasian M, Meyer M, Fingert H, et al. Baseline heart rate-corrected QT and eligibility for clinical trials in oncology. J Clin Oncol 2003;21:3378-9
48. Varterasian M, Fingers H, Agin M, Meyer M. Consideration of QT/QTc interval data in a Phase I study in patients with advanced cancer. Clin Cancer Res 2004;10:5967-70
49. Sarapa N, Huang X, Varterasian M, Fingert H. Risk management and eligibility criteria for QTc assessment in patients with advanced cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23:3047
50. Barbey JT, Pezzulo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 2003;21:3609-15
51. Curigliano G, Spitaleri G, Fingers HJ, et al. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J Cancer 2007:44(4):494-500
52. Committee for Proprietary Medicinal Products (CPMP). Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products; London, UK. 1997 December 17. Available from: http://tga.health.gov.au/docs/pdf/euguide/swp/ 098696en.pdf
53. ICH S7B Guidance for Industry: The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. International Conference on Harmonization. 2004 June. Available from: http://wwwfda.gov/cder/ guidance/5533dft.htm
54. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45
55. Toyoshima S, Kanno A, Kitayama T, et al. QT PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. J Pharmacol Sci 2005;99:459-71
56. Ando K, Hombo T, Kanno A, et al. QT PRODACT: in vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation. J Pharmacol Sci 2005;99:487-500
57. Kurzrock R, Benjamin JS. Risks and benefits of oncology phase 1 trials, revisited. N Engl J Med 2005;352:930-2
58. Drolet B, Simard C, Roden DM. Unusual effects of a QT-prolonging drug, arsenic trioxide on cardiac potassium channels. Circulation 2004;109:26-9
59. Thomas D, Hammerling BC, Wu K, et al. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action. Br J Pharmacol 2004;142:485-94
60. Soria JC, Dieras V, Girre V, et al. QTc monitoring during a phase I study: experience with SR271425. Am J Clin Oncol 2007;30:106-12
61. Fumoleau P, Campone M, Isambert N, et al. A phase-I dose-escalation study of SR271425 administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors [Abstract # 3133]. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(Suppl):3133
62. Velcade Phase IV trial could expand label to first-line multiple myeloma. Pink Sheet 2003;6520:5
63. Patterson SD, Agin M, Anziano R, et al. Investigating drug-induced QT and QTc prolongation in the clinic: a review of statistical design and analysis considerations: Report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team. Drug Inf J 2005;39:243-66
64. Patterson SD, Jones B, Zariffa N. Modeling and interpreting QTc prolongation in clinical pharmacology studies. Drug Inf J 2005;39:437-45
65. Piotrovsky V. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J 2005;7:E609-24
66. Siu CW, Au WY, Yung C, et al. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: Implications for long-term cardiac safety. Blood 2006;108:103-6
67. Hutmacher MM, Chapel S, Agin MA, et al. Performance characteristics for some typical qt study designs under the ICH E-14 guidance. J Clin Pharmacol 2008;48:215-24
68. Garnett CE, Beasley N, Bhattaram VA, et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 2008;48:13-8
69. Russell T, Riley SP, Cook JA, Lalonde RL. A perspective on the use of concentration-QTc modeling in drug development. J Clin Pharmacol 2008;48:9-12
70. Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometric reviews on new drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J 2005;7:E503-12
71. Bhattaram VA, Bonapace C, Chilukuri DM, et al. Impact of pharmacometric reviews on new drug approval and labeling decisions - a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther 2007;81:213-21
72. Cantilena LR, Koerner J, Temple R, Throckmorton DC. FDA evaluation of cardiac repolarization data for 19 drugs and drug candidates. Clin Pharm Ther 2006;79:29
73. Malik M. Detection of drug-induced proarrhythmia: Balancing preclinical and clinical studies. Heart Rhythm 2005;2:773-6
74. Cavero I, Crumb W. ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis. Expert Opin Drug Saf 2005;4:509-30
75. Martinelli E, Takimoto C, van Oosterom A, et al. AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: preliminary phase 1 results. ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(16S):3039
76. McKeage MJ, Fong P, Jeffery M, et al. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 2006;12:1776-84
77. Shigeno K, Naito K, Sahara N, et al. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: Updated outcomes of the phase II study and postremission therapies. Int J Hematol 2005;82:224-9
78. Naito K, Kobayashi M, Sahara N, et al. Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy. Int J Hematol 2006;83:318-23
79. Morganroth J. Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther 2007;81:108-13
80. Sarapa N, Nickens DJ, Raber SR, et al. Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies. Clin Pham Ther 2007;83:153-9
81. Morganroth J, Ilson BE, Shaddinger BC, et al. Evaluation of Vardenafil and Sildenafil on Cardiac Repolarization. Am J Cardiol 2004;93:1378-83
82. Bello CL, Rosen LS, Mulay M, et al. Characterization of electrocardiographic QTc interval in patients (pts) with advanced solid tumors: pharmacokinetic-pharmacodynamic evaluation of sunitinib. Eur J Cancer Suppl 2007;5:110
83. Boike SC, Ilson B, Zariffa N, et al. Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetronin healthy adults. Am J Health Syst Pharm 1997;54:1172-6
84. Ixempra™ (ixabepilone) Package Insert. Bristol Myers Squibb, Princeton, NJ, USA. 2007 October 16. Available from: http://www.fda.gov/ cder/foi/label/2007/022065lbl.pdf
85. US Food and Drug Administration. NDA approval letter for Ixempram™(ixabepilone). 2007. Available from: http://www.fda.gov/ cder/foi/appletter/2007/022065s000ltr.pdf
86. Sun H, Chen P, Hunt J, Malinowski H. Frequency of QT recording and reliability of QT prolongation assessment. Clin Pharm Ther 2004;75:48
87. Agin MA, Kazierad DJ, Abel R, et al. Assessing QT variability in healthy volunteers. J Clin Pharm 2003;43:1028
88. Couderc JP, Xiaojuan X, Zareba W, et al. Assessment of the stability of the individual-based correction of qt interval for heart rate. Ann Noninvasive Electrocardiol 2005;10:25-34
89. Fridericia L. Die systolen dauer im elektrokardiogramm bei normalen menschen und bei herzkranke. Acta Med Scand 1920;53:469-74
90. Plenaxis™ (abarelix) for injectable suspension; Manufacturer: Praecis Pharmaceuticals Inc. Little Falls, NJ, USA). FDA Clinical Pharmacology and Biopharmaceutics Review, 2003. Available from: http://www.fda.gov/cder/foi/nda/2003/21-320_Plenaxis_Biopharmr.pdf
91. FDA Digital ECG Initiative: "Providing Digital Electrocardiogram (ECG) Data" 2001. Available from: http://www.fda.gov/cder/ regulatory/ersr/default.htm
92. Stockbridge N, Brown BD. Annotated ECG waveform data at FDA. J Electrocardiol 2004;37(Suppl):63-4
93. Temple R. Quantitative decision analysis: a work in progress. Clin Pharm Ther 2007;82:127-30
94. Committee for Human Medicinal Products (CHMP). Report of the CHMP Working Group on benefit-risk assessment models and methods. CHMP, 2007 February 19. Available from: http://www.emea.europa.eu/pdfs/human/ brmethods/1540407en.pdf
95. Honig P. Benefit and risk assessment in drug development and utilization: A role for clinical pharmacology. Clin Pharm Ther 2007;82:109-12
96. Trisenox™ (arsenic trioxide) Package Insert. Cephalon, Inc, Frazer, PA, USA [update 2006 July]. Available from: http://www.trisenox.com/pdf/ TRISENOX_pi.pdf
97. Stockbridge N. Cardiac safety evaluations of large molecules: An FDA perspective. Presentation to Pharmaceutical Executive. 2008 February 26. Available from: http://event.on24.com/event/99/29/7/rt/1/documents/ slidepdf/quintiles_presentation_slides_v2.pdf